Uribe FJD, Hernández JM, Guevara DJ, Segura X

Language: Spanish
References: 28
Page: 192-199
PDF size: 265.97 Kb.

ABSTRACT

Objective: To compare losartan and enalapril on reduction of left ventricular hypertrophy. Material and methods: Longitudinal, prospective, comparative, controlled study, of patients with moderate systemic arterial hypertension and echocardiographically proven left ventricular hypertrophy, randomized for treatment during six months with losartan 100 mg daily or enalapril 20 mg daily. The reduction of left ventricular mass index, was evaluated by echocardiogram basal and to six months. Statistical analysis: Student´s t, Spearman and Pearson correlation coefficients. Results: 85 patients finished the study (43 in the losartan group and 42 in the enalapril group). After six months of treatment, the blood pressure values and the left ventricular mass index decreased in losartan and enalapril (p= .0000001 y .00001 respectively), without significative difference in the intergrupal comparative. We found correlation between diastolic and media blood pressure reduction (but not for systolic) and the decrease in left ventricular mass index in both groups. Conclusions: Both drugs were equally effective for control systemic arterial hypertension and produced a significant reduction of left ventricular hypertrophy, with modification of geometrical pattern to short time.

REFERENCES

1. Frohlich ED: Mechanisms of risk in hypertensive heart disease. Hypertension 1999; 34: 782-789.

2. Frohlich ED: Current clinical pathophysiologic considerations in essential hypertension. Med Clin North Am 1997; 81: 1113-1129.

3. Carretero OA, Oparil S: Essential hypertension. Part I: definition and etiology. Circulation 2000; 101: 329-335.

4. Messerli FH, Arístizabal D, Soria F: Reduction of left ventricular hypertrophy: how beneficial? Am Heart J 1993; 125: 1520-1524.

5. Morgan HE, Baker KM: Cardiac hypertrophy: mechanical, neural and endocrine dependence. Circulation 1991; 83: 13-25.

6. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man: anatomic validation of method. Circulation 1977; 55: 613-618.

7. Liebson PR, Savage DD: Echocardiography in hypertension: a review. Echocardiography 1986; 3: 181-213.

8. Devereux RB, Lutas EM, Casale PN: Standardization of M- mode echocardiographic left ventricular measurements. J Am Coll Cardiol 1984; 4: 1222-1230.

9. Coca A, Giner V: Antihypertensive advantages of angiotensin II AT1 receptor antagonism. Rev Esp Cardiol 1999; 5: 53-58.

10. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513.

11. Frohlich ED: Is reversal of left ventricular hypertrophy in hypertension beneficial. Hypertension 1991; 18: 133-138.

12. Dahlof B, Pennert K, Hansson L: Regression of left ventricular hypertrophy: a meta-analysis. Clin Exp Hypertens 1992; 14: 173-180.

13. Devereux RB: Therapeutic options in minimizing left ventricular hypertrophy. Am Heart J 2000; 139: S9-S14.

14. Devereux RB: Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy. Circulation 1997; 95: 1983-1985.

15. Devereux RB, Dahlof B, Levy D: Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension. Am J Cardiol 1996; 78: 61-65.

16. Konstam MA, Patten RD, Thomas I: Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J 2000; 139: 1081-1087.

17. Lièvre M, Guéret P, Gayet C, Roudaut R, Haugh MC, Delair S: Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995; 25: 92-97.

18. Carretero OA, Oparil S: Essential hypertension. Part II. Treatment. Circulation 2000; 101: 446-453.

19. Tikkanen I, Omvik P, Jensen HE: Comparison of the angiotensin II antagonism losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertension 1995; 13: 1343-1351.

20. Devereux RB, Dahlöf B: Criteria for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens 1994; 8: 735-739.

21. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167-1176.

22. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. National Institutes of Health. USA 1997.

23. Azizi M, Guyene TT, Chateller G, Ménard J: Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects. Clin Exp Hypertension 1997; 19: 937-51.

24. Azizi M, Guyene TT, Chatellier G, Wargon M, Ménard J: Additive effects of losartan and enalapril on blood pressure and plasma active rennin. Hypertension 1997; 29: 634-40.

25. Gottdiener JS, Reda DJ, Massie BM: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 1997; 95: 2007-2014.

26. Ruff D, Gazdick LP, Berman R: Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist or enalapril maleate for the treatment of severe hypertension. J Hypertension 1996; 14: 263-270.

27. Burnier M, Waeber B, Brunner HR: The advantages of angiotensin II antagonism. J Hypertens 1994; 12: 57-65.

28. Baker KM, Cherin MI, Wixon SK: Renin angiotensin system involvement in pressure- overload cardiac hypertrophy in rats. Am J Physiol 1990; 259: 324-332.